

References

1. Rawla P and Samant H. Primary Sclerosing Cholangitis. [Updated 12 Feb 2023]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK537181/>
2. Bakhshi Z *et al.* An update on primary sclerosing cholangitis epidemiology outcomes and quantification of alkaline phosphatase variability in a population-based cohort. *Journal of Gastroenterology* 2020;55(5):523–32.
3. Arizumi T *et al.* Present status of primary sclerosing cholangitis in Japan: A nationwide survey. *Hepatology International* 2016;10(1):S38.
4. Barner-Rasmussen N *et al.* Epidemiology risk of malignancy and patient survival in primary sclerosing cholangitis: a population-based study in Finland. *Scandinavian Journal of Gastroenterology* 2020;55(1):74–81.
5. Carbone M *et al.* Primary sclerosing cholangitis: Burden of disease and mortality using data from the national rare diseases registry in Italy. *International Journal of Environmental Research and Public Health* 2020;17(9):3095.
6. Tanaka A *et al.* Increase trend in the prevalence and male-to-female ratio of primary biliary cholangitis autoimmune hepatitis and primary sclerosing cholangitis in Japan. *Hepatology Research* 2019;49(8):881–9.
7. Yanai H *et al.* Prognosis of primary sclerosing cholangitis in Israel is independent of coexisting inflammatory bowel disease. *Journal of Crohn's and Colitis* 2015;9(2):177–84.
8. Dyson JK *et al.* Hunting the environmental trigger in primary sclerosing cholangitis: Disease clustering with affluence and rural location. *United European Gastroenterology Journal* 2018;6(8):A73–4.
9. Fraga M *et al.* Primary sclerosing cholangitis in the Swiss Inflammatory Bowel Disease Cohort Study: Prevalence risk factors and long-term follow-up. *European Journal of Gastroenterology and Hepatology* 2017;29(1):91–7.

10. Freeman E *et al.* Long-term outcomes of primary sclerosing cholangitis: an Australian non-transplant tertiary hospital perspective. *Internal Medicine Journal* 2019;49(3):323–7.
11. Goldberg DS *et al.* Characteristics of North American patients with primary sclerosing cholangitis: Results from the Consortium for Autoimmune Liver Diseases (CALiD). *Hepatology* 2019;70(suppl.1):799A.
12. Goode EC *et al.* Early clinical features associated with long-term risk of transplantation in primary sclerosing cholangitis: Results from the UK-PSC consortium. *Journal of Hepatology* 2015;62:S230–1.
13. Haj M, Bickford MM & Forster EM. Race influences clinical outcomes of patients with primary sclerosis cholangitis and inflammatory bowel disease. *Gastroenterology* 2020;158(6):S-444–5.
14. Jegadeesan R *et al.* Impact of concurrent non-IBD immunological diseases on the outcome of primary sclerosing cholangitis. *Inflammatory Bowel Diseases* 2016;22(4):948–54.
15. Liu K *et al.* Epidemiology and outcomes of primary sclerosing cholangitis with and without inflammatory bowel disease in an Australian cohort. *Liver International* 2017;37(3):442–8.
16. Martins C *et al.* Clinical outcomes of primary sclerosing cholangitis in IBD patients: A single center experience. *American Journal of Gastroenterology* 2019;114:S3.
17. Sørensen J *et al.* Inflammatory bowel disease with primary sclerosing cholangitis: A Danish population-based cohort study 1977-2011. *Liver International* 2018;38(3):532–41.
18. Trivedi PJ *et al.* Defining the unmet need in primary sclerosing cholangitis: The international PSC group risk stratification study. *Gut* 2016;65:A18.
19. Waghray AA, Michel-Calderon A and Waghray N. Primary sclerosing cholangitis in inflammatory bowel disease: Evaluating the disease characteristics and distribution. *Gastroenterology* 2015;148(4):S133–4.
20. Webb G and Hirschfield G. Co-prevalent autoimmunity varies between autoimmune liver diseases: A primary care practice database study. *Hepatology* 2019;70(suppl.1):865A.

21. Weismüller TJ *et al.* Impact of geographical region on death or transplantation and on malignancy in primary sclerosing cholangitis-a multicenter retrospective study of the international PSC study group (IPSCSG). *Hepatology* 2018;68:1079A–80A.
22. Weismüller TJ *et al.* Patient age, sex, and inflammatory bowel disease phenotype associate with course of primary sclerosing cholangitis. *Gastroenterology* 2017;152(8):1975–84.e8.
23. Lundberg Båve A *et al.* Increased risk of cancer in patients with primary sclerosing cholangitis. *Hepatology International* 2021;15(5):1174–82.
24. Webb G *et al.* Autoimmune liver disease in the UK: A national primary care evaluation of disease geoepidemiology. *Hepatology* 2017;66:186A.
25. Guerra I *et al.* Clinical characteristics, associated malignancies and management of primary sclerosing cholangitis in inflammatory bowel disease patients: A multicentre retrospective cohort study. *Journal of Crohn's and Colitis* 2019;13(12):1492–1500.
26. Lamba MJ, Hieng Ngu J and Stedman CAM. Trends in incidence of autoimmune liver diseases and increasing incidence of autoimmune hepatitis. *Clinical Gastroenterology and Hepatology* 2021;19(3):573–9.e1.
27. Liang H *et al.* Incidence, prevalence, and natural history of primary sclerosing cholangitis in the United Kingdom. *Medicine (Baltimore)* 2017;96(24):e7116.
28. Azzam NA *et al.* Epidemiology of primary sclerosing cholangitis in inflammatory bowel disease: A longitudinal Saudi cohort study. *Saudi Journal of Gastroenterology* 2017;23(7):S9.
29. Martins CA *et al.* Clinical presentation and outcomes of primary sclerosing cholangitis and autoimmune hepatitis in inflammatory bowel disease. *Gastroenterology* 2020;158(6):S-732–3.
30. Silva J *et al.* Frequency of hepatobiliary manifestations and concomitant liver disease in inflammatory bowel disease patients. *BioMed Research International* 2019;7604939.
31. Trivedi *et al.* Nationwide population-based evaluation of mortality and cancer-risk in young patients with ulcerative colitis/primary sclerosing cholangitis. *Gut* 2018;67:A103–4.

32. Lundberg Båve A *et al.* Autoimmune comorbidity in primary sclerosing cholangitis is highly prevalent but not associated with severe outcome. *Hepatology* 2021;74(suppl.1):746A.
33. Fevery J *et al.* Patients with large-duct primary sclerosing cholangitis and Crohn's disease have a better outcome than those with ulcerative colitis or without IBD. *Alimentary Pharmacology and Therapeutics* 2016;43(5):612–20.
34. Tabarsi N *et al.* Current practices in screening for complications of primary sclerosing cholangitis: A single-centre retrospective analysis. *Canadian Journal of Gastroenterology and Hepatology* 2016;2016:121
35. Ambelil M *et al.* Histological changes of early primary sclerosing cholangitis in patients undergoing colon resection for inflammatory bowel disease. *Modern Pathology* 2019;32(3).
36. Hellström A and Färkkilä MA. Clinical characteristics of inflammatory bowel disease diagnosed before or after of primary sclerosing cholangitis (PSC): Effect on PSC outcome. *United European Gastroenterology Journal* 2016;4(5):A612.
37. Watanabe T *et al.* Short-term prognostic factors for primary sclerosing cholangitis. *Journal of Hepato-Biliary-Pancreatic Sciences* 2015;22(6):486–90.
38. Ali AH *et al.* Association between baseline serum alkaline phosphatase normalization of alkaline phosphatase and colorectal cancer risk in primary sclerosing cholangitis. *Gastroenterology* 2016;150(4):S1057.
39. Hilscher M *et al.* Alkaline phosphatase normalization is a biomarker of improved survival in primary sclerosing cholangitis. *Annals of Hepatology* 2016.15(2);246–53.
40. Ismail M *et al.* North American evaluation of 2519 patients with primary sclerosing cholangitis: longitudinal patterns of disease activity identify and validate stable and progressive phenotypes. *Journal of Hepatology* 2022;77:S62.
41. Gomel R *et al.* Medical treatments in patients with primary sclerosing cholangitis differ between Europe and North America. *Journal of Hepatology* 2016;64(2):S641.

42. Kuo A *et al.* Characteristics and outcomes reported by patients with primary sclerosing cholangitis through an online registry. *Clinical Gastroenterology and Hepatology* 2019;17(7):1372–8.
43. Stokkeland K *et al.* Statin use is associated with improved outcomes of patients with primary sclerosing cholangitis. *Clinical Gastroenterology and Hepatology* 2019;17(9):1860–6.e1.
44. Cheung AC *et al.* Factors that influence health-related quality of life in patients with primary sclerosing cholangitis. *Digestive Diseases and Sciences* 2016;61(6):1692–9.
45. Raszeja-Wyszomirska J *et al.* Prospective evaluation of PBC-specific health-related quality of life questionnaires in patients with primary sclerosing cholangitis. *Liver International* 2015;35(6):1764–71.
46. Van Munster K *et al.* Health status and disease burden in primary sclerosing cholangitis are mainly determined by fatigue and pruritus. *Hepatology* 2017;66:182A.
47. Andersen IM *et al.* Indications and outcomes in liver transplantation in patients with primary sclerosing cholangitis in Norway. *Transplantation Direct* 2015;1(9):e39.
48. Shah S *et al.* Fenofibrate and PSC: A case series from a single center liver registry. *American Journal of Gastroenterology* 2019;114:S1544–5.
49. Levy C *et al.* Prospective evaluation of serum gamma-glutamyl transferase (GGT) for the prediction of disease progression in a randomized trial of patients with primary sclerosing cholangitis (PSC). *Journal of Hepatology* 2018;68:S568.
50. Nilsson E *et al.* Clinical course and mortality by etiology of liver cirrhosis in Sweden: a population based long-term follow-up study of 1317 patients. *Alimentary Pharmacology and Therapeutics* 2019;49(11):1421–30.
51. Dyson JK *et al.* Fatigue in primary sclerosing cholangitis is associated with sympathetic over-activity and increased cardiac output. *Liver International* 2015;35(5):1633–41.
52. Walmsley M *et al.* Identifying research priorities in primary sclerosing cholangitis: Driving clinically meaningful change from the patients' perspective. *Journal of Hepatology* 2019;70(1):e412–3.

53. Haapamäki J *et al.* Health-related quality of life among patients with primary sclerosing cholangitis. *Liver International* 2015;35(9):2194–201.
54. Kalaitzakis E *et al.* Mapping chronic liver disease questionnaire scores onto SF-6D utility values in patients with primary sclerosing cholangitis. *Quality of Life Research* 2016;25(4):947–57.
55. Ajayi T *et al.* Clinical characteristics and outcomes in primary sclerosing cholangitis following liver transplantation - a single center experience. *Gastroenterology* 2018;154(6): S-1212.
56. Barner-Rasmussen N and Färkkilä MA. Survival of primary sclerosing cholangitis: A population-based study in Finland. *United European Gastroenterology Journal* 2018;6(8):A72.
57. Bhardwaj G *et al.* Ulcerative colitis with PSC have higher mortality higher healthcare utilization and worse clinical outcomes compared to UC only patients: National inpatient sample. *American Journal of Gastroenterology* 2016;111:S289.
58. Emek E *et al.* Experience in liver transplantation due to primary sclerosing cholangitis: a single center experience. *Transplantation Proceedings* 2019;51(7):2439–41.
59. Franceschet I *et al.* Primary sclerosing cholangitis associated with inflammatory bowel disease: An observational study in a Southern Europe population focusing on new therapeutic options. *European Journal of Gastroenterology and Hepatology* 2016;28(5):508–13.
60. Haseeb A *et al.* Elevated serum bilirubin level correlates with the development of cholangiocarcinoma subsequent liver transplantation and death in patients with primary sclerosing cholangitis. *Journal of Clinical Gastroenterology* 2016;50(5):431–5.
61. Liang H *et al.* Natural history of primary sclerosing cholangitis - A study using the UK Clinical Practice Research Datalink (CPRD GOLD). *Pharmacoepidemiology and Drug Safety* 2016;25:115.

62. Lindström L *et al.* Risk factors and prognosis for recurrent primary sclerosing cholangitis after liver transplantation: a Nordic Multicentre Study. *Scandinavian Journal of Gastroenterology* 2018;53(3):297–304.
63. Öztaş E *et al.* Comparative assessment of prognostic value for revised-mayo risk model and child-pugh score in patients with primary sclerosing cholangitis. *Turkish Journal of Gastroenterology* 2015;26(1):31–5.
64. Kapuria D *et al.* National trends of malignancy-related hospitalizations associated with primary sclerosing cholangitis: A 15-year report. *Hepatology* 2019;70(suppl.1):780A–781A.
65. Bolliet M *et al.* Cholangiocarcinoma and colorectal cancer in patients with primary sclerosing cholangitis and/or inflammatory bowel disease: A retrospective study (1985-2014). *Gastroenterology* 2016;150(4):S919.
66. Dyson J *et al.* The ongoing challenge of hepatobiliary malignancy in primary sclerosing cholangitis. *Hepatology* 2019;70(suppl.1):801A–802A.
67. Lindström L *et al.* Recurrence of PSC after liver transplantation in the Nordic countries. *Journal of Hepatology* 2015;62:S781–2.
68. Manninen P *et al.* Colorectal cancer and cholangiocarcinoma in patients with primary sclerosing cholangitis and inflammatory bowel disease. *Scandinavian Journal of Gastroenterology* 2015;50(4):423–8.
69. Mouchli M *et al.* Rate risk factors and outcomes of biliary strictures after liver transplantation for primary sclerosing cholangitis. *American Journal of Gastroenterology* 2016;111:S367.
70. Mousa OY *et al.* Survival outcomes of liver transplant patients with primary sclerosing cholangitis and inflammatory bowel disease. *American Journal of Gastroenterology* 2017;112:S511–2.
71. van Erp LW *et al.* Risk of gallbladder cancer in patients with primary sclerosing cholangitis and radiographically detected gallbladder polyps. *Liver International* 2020;40(2):382–92.

72. Abdalla M *et al.* Risk and location of colorectal cancer in patients with inflammatory bowel disease with and without concomitant primary sclerosing cholangitis: A national Swedish cohort study. *Colorectal Disease* 2019;21:32.
73. Cordes F *et al.* Distinct disease phenotype of ulcerative colitis in patients with coincident primary sclerosing cholangitis: evidence from a large retrospective study with matched cohorts. *Diseases of the Colon and Rectum* 2019;62(12):1494–504.
74. Hamdeh S *et al.* Does inflammatory bowel disease increase the risk of malignancies in patients with primary sclerosing cholangitis: A systematic review and meta-analysis. *American Journal of Gastroenterology* 2016;111:S298–9.
75. Irlès-Depé M *et al.* Impact of pre-existing inflammatory bowel disease on the outcome of liver transplantation for primary sclerosing cholangitis. *Liver Transplantation* 2020;26(11):1477–91.
76. Jelaković M *et al.* Extracolonic and colonic cancer risk in patients with ulcerative colitis and primary sclerosing cholangitis. *Journal of Crohn's and Colitis* 2017;11:S464.
77. Loftus EV *et al.* Natural history of established and de novo inflammatory bowel disease after liver transplantation for primary sclerosing cholangitis. *Inflammatory Bowel Diseases* 2018;24(5):1074–81.
78. Navaneethan U *et al.* Primary sclerosing cholangitis and the risk of colon neoplasia in patients with Crohn's colitis. *Gastroenterology Report (Oxf)* 2016;4(3):226–31.
79. Nordin A *et al.* Decreasing incidence of cancer after liver transplantation—A Nordic population-based study over 3 decades. *American Journal of Transplantation* 2018;18(4):952–63.
80. Shah SC *et al.* High risk of advanced colorectal neoplasia in patients with primary sclerosing cholangitis associated with inflammatory bowel disease. *Clinical Gastroenterology and Hepatology* 2018;16(7):1106–13.e3.
81. Soerensen JO *et al.* Clinical features and prognosis of coexisting inflammatory bowel disease and primary sclerosing cholangitis: A population-based cohort study 1977-2011. *Gastroenterology* 2015;148(4):S464.

82. Bove V *et al.* Endotherapy in patients with primary sclerosing cholangitis: Over 30 years' experience. *Digestive Endoscopy* 2020;32:165.
83. Fosby B *et al.* Liver transplantation in the Nordic countries - An intention to treat and post-transplant analysis from the Nordic Liver Transplant Registry 1982-2013. *Scandinavian Journal of Gastroenterology* 2015;50(6):797–808.
84. Henson JB *et al.* Outcomes of liver retransplantation in patients with primary sclerosing cholangitis. *Liver Transplantation* 2017;23(6):769–80.
85. Henson JB *et al.* Differences in phenotypes and liver transplantation outcomes by age group in patients with primary sclerosing cholangitis. *Digestive Diseases and Sciences* 2017;62(11):3200–9.
86. Kwong AJ *et al.* Number of cholangitis episodes predicts mortality in primary sclerosing cholangitis. *Hepatology* 2021;74(suppl.1):771A–2A.
87. Staufer K *et al.* Waitlist mortality and post-transplant survival in patients with cholestatic liver disease - Impact of changes in allocation policy. *HPB (Oxford)* 2018;20(10):916–24.
88. Astarcioglu I. *et al.* Liver transplant in patients with primary sclerosing cholangitis: Long-term experience of a single center. *Experimental and Clinical Transplantation* 2018;16(4):434–8.
89. Njei B *et al.* Cost utility of ERCP-based modalities for the diagnosis of cholangiocarcinoma in primary sclerosing cholangitis. *Gastrointestinal Endoscopy* 2017;85(4):773–81.
90. Harries L *et al.* High resource utilization in liver transplantation—how strongly differ costs between the care sectors and what are the main cost drivers?: A retrospective study. *Transplant International* 2017;30(6):621–37.
91. Bajer L *et al.* Risk of recurrence of primary sclerosing cholangitis after liver transplantation is associated with de novo inflammatory bowel disease. *World Journal of Gastroenterology* 2018;24(43):4939–49.

92. Bajer L *et al.* De-novo inflammatory bowel disease is a significant risk factor for primary sclerosing cholangitis recurrence after liver transplantation. *Journal of Crohn's and Colitis* 2016;10:S461–2.
93. Choudhary NS *et al.* Good long-term outcomes in patients with primary sclerosing cholangitis undergoing living donor liver transplantation. *Journal of Clinical and Experimental Hepatology* 2020;10(5):442–7.
94. Dekkers N *et al.* Does mucosal inflammation drive recurrence of PSC in liver transplant recipients with ulcerative colitis? *Journal of Crohn's and Colitis* 2018;12:S209.
95. Drastich P *et al.* Risk factors for primary sclerosing cholangitis recurrence after orthotopic liver transplantation. *Transplantation* 2016;100(7):S253.
96. Hildebrand T *et al.* Biliary strictures and recurrence after liver transplantation for primary sclerosing cholangitis: A retrospective multicenter analysis. *Liver Transplantation* 2016;22(1):42–52.
97. Hooper A and Frenette C. Steroid-free immunosuppression after liver transplant for autoimmune disease does not result in increased disease recurrence. *American Journal of Transplantation* 2017;17:783.
98. Hu X *et al.* Patients with recurrent primary sclerosing cholangitis after liver transplantation: An Australian 30-year cohort study. *Journal of Gastroenterology and Hepatology* 2019;34:96.
99. Jegadeesan R *et al.* Anti-tumor necrosis factor treatment of inflammatory bowel disease in patients with primary sclerosing cholangitis and inflammatory bowel disease. *Gastroenterology* 2016;150(4):S396–7.
100. Kumar S *et al.* Outcomes following liver retransplantation in primary sclerosing cholangitis. *Hepatology* 2016;64(1):491A.
101. Lita M *et al.* Female predominance low rate of primary sclerosing cholangitis-IBD phenotype low rate of dominant strictures cholangiocarcinoma and need for transplantation. *Journal of Hepatology* 2016;64(2):S637.

102. Mouchli M *et al.* Short and long-term patient and graft outcomes after liver transplantation for primary sclerosing cholangitis in the new era of transplantation. *Gastroenterology* 2018;154(6):S-1211.
103. Mouchli MA *et al.* Rate risk factors and outcomes of recurrence of primary sclerosing cholangitis after liver transplantation. *American Journal of Gastroenterology* 2015;110:S902.
104. Numan L *et al.* Primary sclerosing cholangitis recurrence after liver transplantation: a systematic review and meta-analysis. *Gastroenterology* 2020;158(6):S-1344.
105. Schoech M and Sherman K. Risk factors for recurrent primary sclerosing cholangitis (RPSC) after orthotopic liver transplant. *American Journal of Gastroenterology* 2019;114:S583–4.
106. Steenstraten IC *et al.* Systematic review with meta-analysis: risk factors for recurrent primary sclerosing cholangitis after liver transplantation. *Alimentary Pharmacology & Therapeutics* 2019;49(6):636–43.
107. Ueda Y *et al.* Long-term prognosis and recurrence of primary sclerosing cholangitis after liver transplantation: a single-center experience. *Transplantation Direct* 2017;3(12):e334.
108. Ravikumar R *et al.* Risk factors for recurrent primary sclerosing cholangitis after liver transplantation. *Journal of Hepatology* 2015;63(5):1139–46.
109. Visseren T *et al.* Recurrence of primary sclerosing cholangitis after liver transplantation – analysing the European Liver Transplant Registry and beyond. *Transplant International* 2021;34(8):1455–67.
110. Visseren T *et al.* Recurrence of primary sclerosing cholangitis is associated with lower survival after liver transplantation: An analysis of the European liver transplant registry data base. *Journal of Hepatology* 2017;66(1):S200.
111. Schuitenmaker JM *et al.* The effect of colectomy on recurrent Primary Sclerosing Cholangitis and need for re-transplantation after orthotopic liver transplantation. *Hepatology* 2017;66:39A.

112. Khan N *et al.* Natural history of ulcerative colitis in patients with concomitant primary sclerosing cholangitis. *American Journal of Gastroenterology* 2017;112:S421–2.
113. Yano K *et al.* Analysis of the disease activity of ulcerative colitis with and without concomitant primary sclerosing cholangitis: An investigation using a nationwide database in Japan. *JGH Open* 2022;6(1):50–6.
114. Nasir UM *et al.* National trends on healthcare utilization in patients with acute inflammatory bowel disease and primary sclerosing cholangitis. *American Journal of Gastroenterology* 2020;115(SUPPL):S460–1.
115. Ramsey M *et al.* Colorectal surgery in inflammatory bowel disease (IBD)-associated colorectal cancer (CRC) with concomitant primary sclerosing cholangitis (PSC) has worse hospital outcomes. *American Journal of Gastroenterology* 2016;111:S311.

Author disclosures

CL has received grant funding and consultant fees from Calliditas Therapeutics, CymaBay Therapeutics, Gilead Sciences, GSK, Intercept Pharmaceuticals, Ipsen Bioscience and Pliant Therapeutics; and has received grant funding from Cara Therapeutics, Escient Pharmaceuticals, GENFIT, HighTide Therapeutics, Mirum Pharmaceuticals, Novartis and Zydus Lifesciences. **CB** has received grant funding and advisor fees from CymaBay Therapeutics, GSK and Ipsen Bioscience; and has received grant funding from Boston Scientific, Calliditas Therapeutics, Cara Therapeutics, Chemomab, COUR Pharmaceuticals, Gilead Sciences, Hanmi Pharmaceuticals, Intercept Pharmaceuticals, Mirum Pharmaceuticals, Novo Nordisk, Pliant Therapeutics and Viking Therapeutics; and has received advisor fees from Invea Therapeutics. **NK** is an employee and stockholder of Gilead Sciences. **GA, SW and CA** are employees of PRMA Consulting who conducted/executed the study on behalf of Gilead Sciences and were paid by Gilead Sciences for their services. **KVK** has received grant funding and consultant fees from CymaBay Therapeutics, GENFIT, Gilead Sciences, Intercept Pharmaceuticals, Madrigal Pharmaceuticals, Mirum Pharmaceuticals, NGM Biopharmaceuticals, Pfizer and 89Bio; has received consultant fees from Enanta Pharmaceuticals, HighTide Therapeutics and Inipharma; has received grant funding from Corcept Therapeutics, GSK, Hanmi Pharmaceutical, Novo Nordisk, Pliant Therapeutics, Terns Pharmaceuticals and Viking Therapeutics; has received speaker bureau honoraria from AbbVie, Gilead Sciences and Intercept Pharmaceuticals; and has stock options with Inipharma.